rucaparib

Rucaparib (PF-01367338) 是一种 PARP 蛋白抑制剂 (PARP-1 Ki=1.4 nM) 和六磷酸己糖脱氢酶 (H6PD) 抑制剂，具有口服活性。Rucaparib 具有抗肿瘤活性，对去势抵抗性前列腺癌 (CRPC) 有活性。

Rucaparib Phosphate (PF-01367338 phosphate) 是一种口服有效的PARP 蛋白抑制剂，对 PARP-1 的Ki 为 1.4 nM。它是六磷酸己糖脱氢酶 (H6PD) 抑制剂，有用于去势抵抗性前列腺癌 (CRPC) 的研究潜力。

Rucaparib monocamsylate (Rucaparib Camsylate) 是一种口服有效的 PARP 蛋白抑制剂，对 PARP-1 的Ki 为 1.4 nM。它是六磷酸己糖脱氢酶 (H6PD) 抑制剂，有用于去势抵抗性前列腺癌 (CRPC) 的研究潜力。

Rucaparib (AG014699) acetate is a highly effective oral inhibitor of PARP proteins, specifically targeting PARP-1, PARP-2, and PARP-3, with a Ki value of 1.4 nM for PARP1. Additionally, it exhibits inhibitory action on hexose-6-phosphate dehydrogenase (H6PD) to a moderate extent. Rucaparib acetate shows promise in the field of research for castration-resistant prostate cancer (CRPC). [1] [2] [3] [4]

Rucaparib (AG014699) camsylate 是一种口服具有活力的 PARP 蛋白 (PARP-1、PARP-2 及 PARP-3) 抑制剂，对 PARP-1 的 Ki=1.4 nM。Rucaparib camsylate 是一种六磷酸己糖脱氢酶 (H6PD) 抑制剂。Rucaparib camsylate 具有潜力进行去势抵抗性前列腺癌 (CRPC) 的研究研究。

Rucaparib hydrochloride, also known as AG014699, is a powerful and orally active compound that inhibits PARP proteins including PARP-1, PARP-2, and PARP-3 with a Ki value of 1.4 nM for PARP1. Additionally, Rucaparib hydrochloride acts as a modest inhibitor of hexose-6-phosphate dehydrogenase (H6PD). This compound shows potential in research for castration-resistant prostate cancer (CRPC) [1] [2] [3] [4].

Rucaparib (AG014699) tartrate 是一种口服具有活力的 PARP 蛋白 (PARP-1, PARP-2 和 PARP-3) 抑制剂，作用于 PARP-1 (Ki: 1.4 nM)。Rucaparib tartrate 是一种六磷酸己糖脱氢酶 (H6PD) 抑制剂。Rucaparib tartrate 具有潜力用于去势抵抗性前列腺癌 (CRPC) 的研究。

iRucaparib-AP6, a non-trapping PARP1 degrader, blocks both the catalytic activity and scaffolding effects of PARP1. iRucaparib-AP6 is a highly efficient and specific PARP1 degrader based on Rucaparib by using the PROTAC approach.

Pomalidomide 4'-PEG3-azide 是一个包含 Pomalidomide 的 cereblon 配体和 1 个 linker 的 E3 连接酶配体-linker 偶联物，可用于 iRucaparib-TP3 的合成。